No Data
No Data
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
Only Three Days Left To Cash In On Dong-E-E-JiaoLtd's (SZSE:000423) Dividend
Dong-E-E-Jiao (000423.SZ): The semi-annual equity distribution for 2024 is 10 payments of 11.47 yuan. Ex-right and ex-dividend date is September 10th.
On September 3, GeLongHui announced that the company's equity distribution plan for the first half of 2024 is as follows: Based on the total existing share capital of 643,976,824 shares, excluding the repurchased shares of 1,512,400 shares, the base number of shares is 642,464,424 shares, and a cash dividend of 11.466930 yuan per 10 shares will be distributed to all shareholders. The equity distribution registration date for this distribution is September 9, 2024, and the ex-dividend date is September 10, 2024.
Dong-E-E-JiaoLtd (SZSE:000423) Shareholders Have Earned a 11% CAGR Over the Last Five Years
Dong-E-E-Jiao H1 Profit Up 39%, Operating Income Rises 27%; Shares Climb 3%
No Data
No Data